Azvudine beats paxlovid in reducing COVID-19 deaths

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.

Pumpkin Safety Tips; Sleep MD Snoozing Tricks; What It’s Like to Date a Resident

The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. It’s pumpkin patch season, which means … potential back injuries?

October 18, 2024

Sotorasib Promising for KRAS–Related Vascular Malformations

Treating severe KRAS G12C-related arteriovenous malformations with sotorasib (Lumakras) appeared to be effective in a small French study. Two adult patients with the life-threatening condition

July 19, 2024

Gerresheimer awarded EcoVadis Gold status again – Biotech Investments

EQS-News: Gerresheimer AG / Key word(s): ESG/Rating Gerresheimer AG: Gerresheimer awarded EcoVadis Gold status again 18.10.2023 / 11:05 CET/CEST The issuer is solely responsible for

October 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.